Skip to main content
Top
Published in: Intensive Care Medicine 1/2014

01-01-2014 | What’s New in Intensive Care Medicine

What can be expected from antimicrobial de-escalation in the critically ill?

Author: Marin H. Kollef

Published in: Intensive Care Medicine | Issue 1/2014

Login to get access

Excerpt

Antimicrobial de-escalation is a clinical approach to empirical antibiotic treatment of serious infections that attempts to balance the need for appropriate initial therapy with the need to limit unnecessary antimicrobial exposure in order to curtail the emergence of resistance [1]. When risk factors for antibiotic resistance are identified in patients with a serious infection, broad-spectrum antimicrobials should be prescribed. A de-escalation approach usually requires initial combination antimicrobial treatment targeting resistant non-fermenting gram-negative bacilli (NFGNB) (Pseudomonas aeruginosa, Acintobacter species) and methicillin-resistant Staphylococcus aureus [2]. However, depending on clinical presentation, patient risk factors, and local epidemiology, other pathogens such as Candida species and Clostridium difficile, especially when diarrhea is present, may also need to be covered. Once the microbiologic results are available and the patient’s clinical response is observed, the antibiotic regimen can be narrowed on the basis of the susceptibilities of the identified pathogens. …
Literature
1.
go back to reference Kollef MH, Micek ST (2005) Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 33:1845–1853PubMedCrossRef Kollef MH, Micek ST (2005) Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 33:1845–1853PubMedCrossRef
2.
go back to reference Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH (2001) Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29:1109–1115PubMedCrossRef Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH (2001) Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29:1109–1115PubMedCrossRef
3.
go back to reference Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group (2003) Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598PubMedCrossRef Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group (2003) Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598PubMedCrossRef
4.
go back to reference Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–1375PubMedCrossRef Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–1375PubMedCrossRef
5.
go back to reference Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474PubMedCrossRef Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474PubMedCrossRef
6.
go back to reference Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM (2009) Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180:861–866PubMedCrossRef Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM (2009) Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180:861–866PubMedCrossRef
7.
go back to reference Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51PubMedCrossRef Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51PubMedCrossRef
8.
go back to reference Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Márquez-Vácaro JA (2013) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. doi:10.1007/s00134-013-3077-7 Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Márquez-Vácaro JA (2013) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. doi:10.​1007/​s00134-013-3077-7
9.
go back to reference Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, Diaz E (2004) De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32:2183–2190PubMed Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, Diaz E (2004) De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32:2183–2190PubMed
10.
go back to reference Thursky KA, Buising KL, Bak N, Macgregor L, Street AC, Macintyre CR, Presneill JJ, Cade JF, Brown GV (2006) Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Int J Qual Health Care 18:224–231PubMedCrossRef Thursky KA, Buising KL, Bak N, Macgregor L, Street AC, Macintyre CR, Presneill JJ, Cade JF, Brown GV (2006) Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Int J Qual Health Care 18:224–231PubMedCrossRef
11.
go back to reference Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188:985–995PubMedCrossRef Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188:985–995PubMedCrossRef
12.
go back to reference Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH (2012) Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54:193–198PubMedCrossRef Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH (2012) Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54:193–198PubMedCrossRef
13.
go back to reference Schuetz P, Mueller B (2013) Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med. doi:10.1007/s00134-013-3139-x Schuetz P, Mueller B (2013) Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med. doi:10.​1007/​s00134-013-3139-x
14.
go back to reference Micek ST, Ward S, Fraser VJ, Kollef MH (2004) A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 125:1791–1799PubMedCrossRef Micek ST, Ward S, Fraser VJ, Kollef MH (2004) A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 125:1791–1799PubMedCrossRef
15.
go back to reference Pulido MR, García-Quintanilla M, Martín-Peña R, Cisneros JM, McConnell MJ (2013) Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother 68:2710–2717 Pulido MR, García-Quintanilla M, Martín-Peña R, Cisneros JM, McConnell MJ (2013) Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother 68:2710–2717
Metadata
Title
What can be expected from antimicrobial de-escalation in the critically ill?
Author
Marin H. Kollef
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 1/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-013-3154-y

Other articles of this Issue 1/2014

Intensive Care Medicine 1/2014 Go to the issue